Puma Biotechnology
Earnings Call
Commercial Update

November 3, 2022
This presentation contains forward-looking statements, including statements regarding commercialization of NERLYNX® and the potential indications and development of our drug candidates. All forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on our current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, which include, but are not limited to, any adverse impact on our business or the global economy and financial markets, generally, from the global COVID-19 pandemic, and the risk factors disclosed in our periodic and current reports filed with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K for the year ended December 31, 2021 and subsequent filings. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We assume no obligation to update these forward-looking statements except as required by law.
PUMA’s Pharmacy and Distributor Network

Hub Services

Patients

Sites of Care
- Academic Hospitals
- Community Hospitals
- Physician Practices
- Others (VA, DOD)

Specialty Pharmacy Network (SP)
- Acaria Health
- Accredro
- CVS
- ONCO 360
- Optum / Diplomat
- Biologics

Specialty Distributor Network (SD)
- McKesson
- ASD/Oncology Supply
- Cardinal Health
- DMS Pharmaceutical Group Inc.
~$54 Million net NERLYNX revenue in Q3’22
3,197 Ex-factory bottles were sold in Q3’22

Bottles Sold (SP + SD) by Quarter

Includes Commercial SP and SD
~68% of patients in Q3’22 started at a reduced dose*  **

*Reduced dose defined as fewer than 6 pills per day

** FDA approved dose-escalation label supplement in June 2021
## Rest of World Partnerships – Timelines

<table>
<thead>
<tr>
<th>Region</th>
<th>Partner</th>
<th>Regulatory Approvals</th>
<th>Commercial Launches</th>
</tr>
</thead>
</table>
| **Australia / SE Asia** | **Specialised Therapeutics** | - 2019 – Ext. Adj. in Australia, Singapore  
- 2020 – Ext. Adj. in Brunei, Malaysia, New Zealand  
- Q2 2022 – Ext. Adj. in the Philippines  
- Q3 2022 – mBC in Singapore | - 2020 – Singapore  
- Q2 2021 – Malaysia  
- Q3 / Q4 2021 – Brunei, New Zealand |
| **Israel**              | **MEDISON** | - 2020 – Approved in Ext. Adj. and mBC                                               | - 2020 – Launched                      |
| **Canada**              | **Knight** | - 2019 – Ext. Adj. approved  
- Q2 2021 – mBC approved                                                      | - 2020 – Launched                      |
| **Latin America**       | **PINT PHARMA** | - 2019 – Ext Adj in Argentina  
- 2020 – Ext. Adj in Chile, Ecuador  
- 2020 – mBC in Argentina  
- 2021 – Ext Adj and mBC in Peru; mBC in Chile  
- Q4 2021 – Ext. Adj. in Brazil  
- Q1 2022 – Ext. Adj. in Mexico  
- Q3 2022 – mBC in Ecuador | - 2020 – Argentina  
- Q2 2021 – Chile  
- Q4 2021 – Peru  
- Q3 2022 – Brazil |
| **Europe**              | **Pierre Fabre** | - 2019 – EMA approval  
- 2019 – Ext. Adj. in Hong Kong  
- 2020 – Ext. Adj. in China, Taiwan  
- Q4 2021 – mBC in Taiwan | - 2019 – Germany, UK, Austria  
- 2020 – Sweden, Finland, Scotland, Switzerland, Denmark  
- 2020 – Hong Kong  
- Q1 2021 – China (added to 2021 NRDL), Taiwan  
- Q1 2021 – Greece, Czech Republic  
- Q1 2022 – Ireland  
- Q3 2022 – Spain |
| **Greater China**       | **BIXINK** | - Q4 2021 – Ext. Adj. in S. Korea                                                     | - Q1 2022 – Launched                    |
| **Middle East**         |           |                                                                                      |                                       |
| **North and West Africa** |         |                                                                                      |                                       |
| **South Africa**        |           |                                                                                      |                                       |
| **Turkey**              |           |                                                                                      |                                       |
| **South Korea**         |           |                                                                                      |                                       |
Puma Biotechnology
Earnings Call
Commercial Update

November 3, 2022